<DOC>
	<DOCNO>NCT03095599</DOCNO>
	<brief_summary>This phase 2/3 , double-blind , placebo-controlled trial 888 adult , age 18 60 year old randomize receive vaccine placebo 5:1 vaccine : placebo randomization .</brief_summary>
	<brief_title>Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial ( IVACFLU-S ) - PHASE 2/3</brief_title>
	<detailed_description>This phase 2/3 , double-blind , placebo-controlled trial 888 adult , age 18 60 year old randomize receive vaccine placebo 5:1 vaccine : placebo randomization . Phase 2 conducted 1 site Long An ( 252 subject ) . Following determination safety vaccine phase 2 study Protocol Safety Review Team ( PSRT ) review approval Vietnam Ministry Health ( MOH ) , Phase 3 enrollment commence 2 site , Long An ( 252 subject ) Dong Nai ( 384 subject ) . Safety assess Phase 2 3 participant Day 91 . Safety data till Day 8 post-vaccination phase 2 study present Protocol Safety Review Team ( PSRT ) evaluation interim report file local institutional review board ( IRB ) MOH . Immunogenicity assess Phase 3 participant . Blood sample collect subset 252 individual randomize one study sit get evaluable sample least 200 vaccine recipient ( 100 age group ) 40 placebo recipient ( 20 age group ) 21 day vaccination . Approximate participant distribution base age , study arm study follow : Age group : Phase 2 2 age group ( 18-45 ; 46-60 ) . In age group , 105 subject receive IVACFLU-S 21 subject receive Placebo , result 126 subject total per age group . Phase 3 2 age group ( 18-45 ; 46-60 ) . In age group , 265 subject receive IVACFLU-S 53 subject receive Placebo , result 318 subject total per age group . Hypotheses : Safety : A single dose seasonal trivalent inactivate split virion influenza vaccine ( IVACFLU-S ) safe well tolerate adult 18 60 year age . Immunogenicity : A single dose seasonal trivalent inactivate split virion influenza vaccine ( IVACFLU-S ) induce immune response three vaccine antigens meet one age group specific Vietnam Ministry Health ( MOH ) licensure requirement . The criterion 18-45 year old HAI seroprotection ( HAI ≥1:40 ) ≥70 % ; 46-60 year old ≥60 % . The criteria seroconversion 18-45 year old ≥40 % ; 46-60 year old ≥30 % . The criterion HAI GMT increase 18-45 year old ≥2.5 time ; 46-60 year old ≥2.0 time .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy stable health Literate If woman become pregnant : willing use reliable contraceptive 3 week injection . Not pregnant breastfeed History hypersensitivity follow vaccination Known suspect congenital acquired immunodeficiency Known tuberculosis symptom active tuberculosis ( self report ) Known allergies component vaccine History GullainBarre</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Vaccine</keyword>
</DOC>